CXCL12/CXCR4 promotes motility and proliferation of glioma cells

Glioblastoma (GBM) is the most aggressive and malignant brain tumor. Recent studies indicated that glioma samples are characterized by increased expression of CXCR4, the CXCL12/SDF-1 chemokine receptor. To better understand the role of CXCR4 in GBM biology we performed an integrated study where we s...

Full description

Saved in:
Bibliographic Details
Published in:Cancer biology & therapy 2010-01, Vol.9 (1), p.56-65
Main Authors: Carmo, Anália do, Patricio, I., Cruz, M.T., Carvalheiro, H., Oliveira, C.R., Lopes, M.C.
Format: Article
Language:English
Subjects:
Binding
Biology
Bioscience
Brain Neoplasms - genetics
Calcium
Cancer
Cell
Cell Line, Tumor
Cell Movement - genetics
Cell Proliferation
Chemokine CXCL12 - genetics
Chemokine CXCL12 - metabolism
Chemotaxis
Cycle
Glioblastoma - pathology
Glioma - genetics
Humans
Landes
Organogenesis
Proteins
Receptors, CXCR4 - genetics
Receptors, CXCR4 - metabolism
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma (GBM) is the most aggressive and malignant brain tumor. Recent studies indicated that glioma samples are characterized by increased expression of CXCR4, the CXCL12/SDF-1 chemokine receptor. To better understand the role of CXCR4 in GBM biology we performed an integrated study where we simultaneously evaluate the contribution of the CXCR4/CXCL12 signaling pathway to the proliferation, survival and motility of a human GBM cell line. Our results indicated that CXCR4/CXCL12 axis induced an increase in cell proliferation and in cell motility. The blockage of CXCR4 induced a significant increase of apoptosis. Together, our results indicated that CXCR4/CXCL12 signalling pathway may contribute to GBM development and emphasize the therapeutic potential of this pathway in patients with GBM.
ISSN:1538-4047
1555-8576
DOI:10.4161/cbt.9.1.10342